Issue 43, 2020

Structural analysis of metastable pharmaceutical loratadine form II, by 3D electron diffraction and DFT+D energy minimisation

Abstract

Metastable polymorphs typically display higher solubility than their thermodynamically stable counterparts, whilst having dissimilar mechanical and biopharmaceutical properties. It is unsurprising then, that generic and innovator companies alike pursue isolation and characterisation of these materials. Here we report the determination of the crystal structure of the metastable form II of loratadine using a combination of low-resolution 3D electron diffraction data and density functional theory. Importantly, electron diffraction was able to establish that the crystallites were phase pure i.e. no other polymorphic forms were identified throughout the sample. 3D data collected at room temperature circumvented potential phase changes, conveniently preserving the metastable polymorph during structural elucidation. The limited resolution of the electron diffraction data (>1 Å), combined with the complexity of configurational disorder and possible beam-induced amorphization, meant that the structure could not be obtained by ab initio direct methods. This is a recurrent situation for nanocrystalline pharmaceutical crystals. Instead, two possible starting models arose from simulated annealing based on diffraction data alone. Density functional theory energy minimisation followed, determining the correct model, with an independent validation of the experimental structural solution, comparing favourably to single-crystal X-ray diffraction studies. Our results reveal a promising protocol enabling the exploitation of electron diffraction data with limited resolution obtained from beam sensitive organic materials. The method is widely extendable to a number of pharmaceutical compounds that are not amenable for the growth of large single crystals required by X-ray diffraction, and for which efficient structure determination is required.

Graphical abstract: Structural analysis of metastable pharmaceutical loratadine form II, by 3D electron diffraction and DFT+D energy minimisation

Supplementary files

Article information

Article type
Paper
Submitted
21 Aug. 2020
Accepted
02 Okt. 2020
First published
02 Okt. 2020

CrystEngComm, 2020,22, 7490-7499

Structural analysis of metastable pharmaceutical loratadine form II, by 3D electron diffraction and DFT+D energy minimisation

G. R. Woollam, P. P. Das, E. Mugnaioli, I. Andrusenko, A. S. Galanis, J. van de Streek, S. Nicolopoulos, M. Gemmi and T. Wagner, CrystEngComm, 2020, 22, 7490 DOI: 10.1039/D0CE01216E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements